StockData
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc. (ELTX) stock

ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$1.59+0.16 (+11.19%)

Close on Nov 18, 2026Market cap $41.79MP/E –Yield –

Elicio Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Elicio Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$37.92M. For fiscal 2025 it was -$37.71M. The highest annual figure on record is -$23.73M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$37.71M–
FY2024Dec 31, 2024-$44.99M–
FY2023Dec 31, 2023-$35.75M–
FY2022Dec 31, 2022-$23.73M–
FY2021Dec 31, 2021-$39.31M–
FY2020Dec 31, 2020-$55.27M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.43M–
Q1 FY2026Mar 31, 2026-$10.60M–
Q4 FY2025Dec 31, 2025-$8.84M–
Q3 FY2025Sep 30, 2025-$8.05M–
Q2 FY2025Jun 30, 2025-$10.09M–
Q1 FY2025Mar 31, 2025-$10.74M–
Q4 FY2024Dec 31, 2024-$13.48M–
Q3 FY2024Sep 30, 2024-$10.34M–
Q2 FY2024Jun 30, 2024-$10.92M–
Q1 FY2024Mar 31, 2024-$10.24M–
Q4 FY2023Dec 31, 2023-$9.39M–
Q3 FY2023Sep 30, 2023-$10.77M–
Q2 FY2023Jun 30, 2023-$7.78M–
Q1 FY2023Mar 31, 2023-$7.81M–
Q4 FY2022Dec 31, 2022-$5.96M-140.7%
Q3 FY2022Sep 30, 2022-$5.77M–
Q2 FY2022Jun 30, 2022-$6.23M–
Q1 FY2022Mar 31, 2022-$14.49M–
Q4 FY2021Dec 31, 2021$14.63M–
Q3 FY2021Sep 30, 2021-$15.76M–
Q2 FY2021Jun 30, 2021-$18.24M–
Q1 FY2021Mar 31, 2021-$19.94M–
Q4 FY2020Dec 31, 2020-$13.85M–
Q3 FY2020Sep 30, 2020-$11.59M–
Q2 FY2020Jun 30, 2020-$17.27M–
Q1 FY2020Mar 31, 2020-$12.57M–

More Elicio Therapeutics figures

See a number that looks wrong?